Solveat

SOLVEAT (SolvEat) is an Israeli food-tech company that develops herbal, or botanical, ingredient compositions intended to turn ordinary foods into functional products aimed at specific health conditions. Its platform combines pharmacological modeling and screening of multi-herb sets, extraction and characterization of bioactive compounds, product design and clinical validation, with a microencapsulation-based delivery system that is presented to manufacturers as a plug-and-play addition to existing formulations. The stated goal of the encapsulation approach is to mask the bitterness of botanicals, withstand heat, preserve bioactivity and allow controlled release while leaving taste, texture and aroma of the host food intact.

The company's lead product, SOLV-S-Balance, is a bioactive functional ingredient designed to help maintain healthy blood sugar levels as part of a regular diet, targeted at people with pre-diabetes and intended for use in chocolate, snacks and beverages. It is a patent-pending composition of eight herbs, including golden thread (Coptis chinensis), Chinese foxglove (Rehmannia glutinosa) and hawthorn berries (Crataegus pinnatifida). A dark chocolate bar prototype sweetened with natural sugar alternatives including monk fruit was produced with the Israeli boutique chocolatier Ornat, Ltd. and introduced at Fi Europe in Frankfurt in November 2023. Additional compositions, including SOLV-Mune for immune system support and an ingredient for metabolic wellness, are in the pipeline, with development work carried out with R&D partner The Hebrew University of Jerusalem.

The team is multidisciplinary, spanning biotechnologists, pharmacists, physicians, food technologists and Chinese medicine practitioners. Co-founder Udi Peretz (MSc) is CEO, co-founder Zacki (Zakhar) Nudelman (PhD, MBA) is CBO and scientific affairs officer, and co-founder Tal Naveh directs herbal medicine. Ilanit Kabessa Cohen chairs the board, which also includes representatives of investor The Trendlines Group.

Founding story

According to co-founder and CEO Udi Peretz, the company originated from his own diagnosis with prediabetes while he was managing a herbal extracts business in China. A local Chinese physician, Prof. Xia Long, advised herbal medicine; the treatment helped but was bitter and required lengthy preparation. Peretz and Prof. Xia concluded that delivering herbal medicine through food would be more convenient and accessible, and Peretz brought the concept to Israel, starting the company at the XLR8 Accelerator and assembling a team that included Dr. Zakhar Nudelman and Traditional Chinese Medicine practitioner Tal Naveh.

Business model

SOLVEAT is a business-to-business ingredient supplier: it licenses or sells its microencapsulated botanical compositions to food and beverage manufacturers, which incorporate them into branded consumer products. Under the CBC agreement, the partner handles manufacturing and commercialization of the resulting branded soft drinks while SOLVEAT provides the formulations and conducts R&D in its own facilities.

Revenue is expected from supplying functional ingredient compositions to manufacturers; the company said it was prepared to begin pilot sales of its blood-sugar-balance composition in early 2026.

Traction

In vitro analysis indicated the composition increased glucose uptake in muscle cells at a low dose of the full formula, with effects comparable to insulin. A preliminary clinical observation of the herb-infused chocolate reported blood sugar reductions of 10 to 24 percent in 10 of 12 prediabetic participants, and a full clinical trial was reported as in progress; as of September 2025 the formula was undergoing clinical assessment with a health organization. The platform was described as operating at industrial scale with capacity for approximately 600 tons of ingredients per year through contract manufacturers, with pilot sales targeted for early 2026.

Latest developments

On 9 September 2025 SOLVEAT announced an investment-based joint development and commercial agreement with The Central Bottling Company (CBC Group) and its juice concentrates subsidiary Gat Foods to create a line of functional still soft drinks addressing categories such as metabolic support and blood sugar control, with R&D run with CBC's CORE open innovation center and clinicians from Sheba Medical Center.